Advertisement

Topics

NeoGenomics and Definiens Enter Into Agreement to Develop Novel Assays for Clinical Trials & Clinical Testing

07:00 EDT 13 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, and Definiens, the leader in Tissue Phenomics® solutions from biomarker discovery to meaningful diagnostics, today announced that t...

Other Sources for this Article

NeoGenomics, Inc.
Steven C. Jones, 239-325-2001
Executive Vice President & Dir. of Investor Relations
or
Definiens
Melissa Baratta, 212-398-9680
Senior Vice President, Affect
mbaratta@affect.com

NEXT ARTICLE

More From BioPortfolio on "NeoGenomics and Definiens Enter Into Agreement to Develop Novel Assays for Clinical Trials & Clinical Testing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...